Luye Pharma Group Ltd. (HKG:2186)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Alimentary Tract and Metabolism Drugs	348.76M	388.87M	450.42M	632.36M	898.46M
Alimentary Tract and Metabolism Drugs Growth	-10.32%	-13.66%	-28.77%	-29.62%	22.50%
Cardio-Vascular System Drugs	1.15B	1.66B	1.69B	1.54B	1.43B
Cardio-Vascular System Drugs Growth	-30.58%	-1.62%	9.87%	7.60%	42.09%
Central Nervous System Drugs	2.03B	1.61B	1.69B	1.32B	1.32B
Central Nervous System Drugs Growth	25.71%	-4.80%	28.12%	-0.08%	-5.55%
Oncology Drugs	2.30B	2.08B	2.12B	2.31B	1.41B
Oncology Drugs Growth	10.20%	-1.78%	-7.96%	63.06%	-36.73%
Others	482.05M	314.67M	188.30M	185.02M	136.61M
Others Growth	53.19%	67.12%	1.77%	35.44%	-17.25%
Total	6.31B	6.06B	6.14B	5.98B	5.20B
Total Growth	4.07%	-1.33%	2.70%	15.03%	-6.13%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Mainland China	5.14B	4.92B	5.03B	5.03B	4.24B
Mainland China Growth	4.29%	-2.09%	-0.03%	18.73%	-6.07%
Asia (Other than Chinese Mainland)	499.10M	347.49M	446.73M	342.47M	443.85M
Asia (Other than Chinese Mainland) Growth	43.63%	-22.21%	30.44%	-22.84%	-12.14%
European Union	538.99M	586.67M	449.98M	309.17M	244.08M
European Union Growth	-8.13%	30.38%	45.54%	26.67%	0.53%
Other Countries	134.49M	202.67M	216.77M	298.85M	274.78M
Other Countries Growth	-33.64%	-6.51%	-27.46%	8.76%	-1.94%
Total	6.31B	6.06B	6.14B	5.98B	5.20B
Total Growth	4.07%	-1.33%	2.70%	15.03%	-6.13%

Source: S&P Global Market Intelligence.